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Abstract: In the last decade, better understanding of the role of epidermal growth  factor  receptor 
in the pathogenesis and progression of non-small cell lung cancer has led to a  revolution in the 
work-up of these neoplasms. Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have 
been approved for the treatment of non-small cell lung cancer, demonstrating an improvement 
in progression-free and overall survival, particularly in patients harboring activating EGFR 
 mutations. Nevertheless, despite initial responses and long-lasting remissions, resistance to 
tyrosine kinase inhibitors invariably develops, most commonly due to the emergence of  secondary 
T790M mutations or to the amplification of mesenchymal–epithelial transition factor (c-Met), 
which inevitably leads to treatment failure. Several clinical studies are ongoing (http://www.
clinicaltrials.gov), aimed to evaluate the efficacy and toxicity of combined approaches and 
to develop novel irreversible or multitargeted tyrosine kinase inhibitors and mutant-selective 
inhibitors to overcome such resistance. This review is an overview of ongoing Phase I, II, and 
III trials of novel small molecule epidermal growth factor receptor inhibitors and combinations 
in non-small cell lung cancer patients.
Keywords: clinical trials, combined targeted therapy, epidermal growth factor receptor, non-
small cell lung cancer, novel targeted agents, tyrosine kinase inhibitors
Background
Lung cancer is the leading cause of cancer-related deaths worldwide, with an annual 
mortality of over 1 million.1,2 Despite the remarkable efforts made to improve screening 
programs for cancer prevention, lung cancer is usually diagnosed as locally advanced or 
metastatic disease.3 Non-small cell lung cancer (NSCLC) accounts for almost 85% of 
all cases and it is further histologically classified as adenocarcinoma (ADC) and its 
variants, squamous cell carcinoma and large-cell carcinoma. Platinum-based chemo-
therapy represents the recommended standard first-line systemic treatment for advanced 
NSCLC,4 although results are limited to a modest increase of survival rates.5
The discovery of activating mutations in the kinase domain of the epidermal growth 
factor receptor (EGFR) gene has determined a revolution in the approach to diagnosis, 
classification, and management of NSCLC. Derangements in the EGFR gene in NSCLC 
result in increased malignant cell survival, proliferation, growth, invasion, metastatic 
spread, apoptosis, and tumor angiogenesis.6–8 These activating mutations are more 
 frequently observed in patients with ADC histology, females, never smokers, and in 
those with Asian ethnicity.9,10 The two most common EGFR mutations are short in-frame 
deletions of exon 19 and a point mutation (CTG to CGG) in exon 21 at nucleotide 257, 
resulting in the substitution of leucine by arginine at codon 858 (L858R).11
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Gefitinib and erlotinib represent the first generation of 
small EGFR tyrosine kinase inhibitors (TKIs) that selec-
tively target the intracellular tyrosine kinase domain of 
EGFR, blocking the downstream signaling of the receptor. 
The EGFR somatic mutations have emerged to be the most 
relevant predictor of response to these agents.12,13 Thus, 
several prospective randomized trials have demonstrated that 
the use of EGFR TKIs in patients with advanced treatment-
naive NSCLC with EGFR mutations significantly improved 
the objective response rate (ORR) and progression-free 
survival (PFS) compared with standard platinum-based 
chemotherapy.14−17
Unfortunately, all responders eventually develop resis-
tance, most commonly because of the emergence of a gate-
keeper mutation in the kinase domain, such as T790M in 
EGFR-mutated NSCLC18 or amplification of mesenchymal–
epithelial transition factor (c-Met).19 Based on these data, 
several ongoing trials are assessing the efficacy and toxicity 
of novel irreversible or multitargeted TKIs and combinations, 
aimed to overcome such resistance.
The aim of this review was to summarize present and 
future strategies in NSCLC. A systematic literature search 
of reviews, articles, abstracts, clinical trials, and extracted 
data was conducted using the following key words: targeted 
therapy, EGFR, EGFR inhibitors, NSCLC, and TKIs.
Overview of ongoing clinical trials  
in NSCLC patients
Over the past few years, NSCLC has become one of the most 
relevant subjects of clinical research worldwide. Current 
efforts are directed toward the identification of novel small 
molecules EGFR inhibitors, to be used alone or in combined 
approaches (Table 1). On December 2012, 2466 clinical trials 
were underway in NSCLC patients, with 629 studies investi-
gating the use of small molecule EGFR inhibitors. Gefitinib 
and erlotinib account for 132 and 334 studies, respectively. 
The other 163 Phase I–III trials include novel EGFR TKIs 
(n = 64), molecular epidemiology studies (n = 54), imag-
ing trials (n = 25), emerging biomarkers of tumor response 
(n = 13), and the prophylaxis and management of TKI-related 
adverse events (AEs) (n = 7). Figure 1 illustrates the distribu-
tion of these studies in the different categories.
In regard to gefitinib, 69 trials are investigating its use 
alone across all lines of therapy or in selected clinical set-
tings (eg, elderly, patients with brain metastasis, different 
ethnicities). Thirty-five studies concern the use of gefitinib 
in combined or sequential strategies with radiotherapy. Five 
studies are investigating gefitinib in the neoadjuvant and 
adjuvant settings, whereas ten trials are being performed 
to assess the efficacy and safety of gefitinib combined with 
chemotherapy regimens. The other 13 ongoing trials focus 
on the use of gefitinib in combination with other targeted 
agents. The details will be described below.
Among the 334 studies on the use of erlotinib in NSCLC, 
166 trials are investigating its use as monotherapy and 79 in 
combined approaches with targeted agents across all lines 
of therapy. The combination of erlotinib and chemotherapy 
is the subject of 36 ongoing trials, whereas 16 studies are 
exploring the use of erlotinib in combined or sequential 
strategies with radiotherapy. The other ongoing trials include 
15 studies in the neoadjuvant (n = 8) or adjuvant (n = 7) 
setting and seven studies on biomarkers of tumor response 
to erlotinib. Figure 2 shows the distribution of gefitinib and 
erlotinib trials in the different categories.
Clinical development of gefitinib  
in NSCLC
Gefitinib is an oral reversible EGFR TKI belonging to the 
small molecule class (quinazoline-derivative molecule).20 It 
inhibits both autophosphorylation and downstream signaling, 
competing reversibly with adenosine triphosphate (ATP) for 
binding to the kinase active site of EGFR. In recent years, 
four randomized Phase III trials have compared gefitinib to 
platinum-based chemotherapy as first-line therapy in patients 
with advanced NSCLC. In EGFR mutation-positive patients, 
the administration of first-line gefitinib was associated with 
longer PFS, higher ORR, a more favorable toxicity profile, 
and better quality of life, with a marginal positive effect on 
survival.6,14,15,21
Maintenance therapy with gefitinib has also been dem-
onstrated to significantly improve PFS following platinum-
based chemotherapy in unselected patients.22 Recently, 
Zhang et al published the results from a multicenter, double-
blind, randomized Phase III trial (NCT00770588) of gefitinib 
(250 mg per day orally) versus placebo in the maintenance 
setting of NSCLC.23 Two-hundred and ninety-six patients 
were enrolled. PFS was 4.8 months and 2.6 months with 
gefitinib and placebo, respectively. The most common 
AEs of any grade in patients treated with gefitinib were 
rash (50%), diarrhea (25%), and alanine aminotransferase 
increase (21%), with three outwardly related-deaths due to 
interstitial lung disease, lung infection, and pneumonia. At 
present, the Genius study (NCT01579630) is ongoing to com-
pare the efficacy and safety of gefitinib/pemetrexed versus 
pemetrexed alone as maintenance therapy in patients EGFR 
mutation-negative or T790M single mutation who responded 
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Table 1 Novel epidermal growth factor receptor inhibitors under evaluation for non-small cell lung cancer (http://www.clinicaltrials.gov)
Agent Description Trial Phase Design
Afatinib Irreversible dual  
EGFR/HER2 inhibitor
NCT00796549 II Advanced EGFR-mutant NSCLC
NCT01647711 I Intermittent high doses of afatinib in advanced T790M-mutant 
NSCLC pts
NCT01553942 II Before chemoradiation and after surgery in Stage III EGFR-
mutant NSCLC
NCT01156545 II Afatinib versus afatinib + simvastatin in previously treated 
non-ADC NSCLC
NCT00730925 II Demographically and genotypically selected NSCLC pts
NCT01480141 II As neoadjuvant therapy in NSCLC pts who are deemed to be 
surgical candidates
NCT01003899 II Third-line therapy for Stage IIIb/IV EGFR-mutant NSCLC pts
Icotinib Potent and specific  
EGFR TKIs
NCT01665417 IV Icotinib as first-line and maintenance therapy in EGFR 
mutated pts with lung ADC
NCT01465243 IV Dose escalation of icotinib in advanced NSCLC after routine 
icotinib therapy
NCT01688713 II NSCLC patients with brain metastasis
NCT01724801 III Icotinib versus whole brain RT in pts with EGFR-mutant NSCLC
NCT01516983 I/II In combination with whole brain RT in pts with EGFR-mutant 
NSCLC
NCT01514877 II In combination with whole brain RT in pts with EGFR-mutant 
NSCLC
NOV120101 Pan-HER inhibitor NCT01718847 II NSCLC patients with acquired resistance to first-generation 
EGFR TKIs
BMS-690514 VEGFR and EGFR TKIs NCT00743938 II BMS-690514 versus erlotinib in previously treated NSCLC pts
NCT01167244 II EGFR mutation-positive NSCLC pts treated with prior 
gefitinib or erlotinib
CO-1686 Irreversible mutant-selective  
inhibitor of EGFR
NCT01526928 I/II Mutant EGFR NSCLC pts previously treated with first-line 
gefitinib or erlotinib
HM61713 Mutant-selective  
EGFR-inhibitor
NCT01588145 I Pts progressed after at least two prior chemotherapy and/or 
EGFR TKI regimens
Dacomitinib Irreversible pan-HER  
inhibitor
NCT01000025 III Dacomitinib versus placebo in Stage IIIB or IV pretreated 
NSCLC pts
NCT00818441 II Selected ADC pts with or without HER2 mutated or 
amplified NSCLC
CUDC-101 Multitarget inhibitor  
of HDAC, EGFR, and HER2
NCT01171924 I Advanced solid tumors including NCSLC
AP26113 Dual ALK/EGFR inhibitor NCT01449461 I/II Advanced solid tumors including NCSLC
XL647 Multiple TKIs, including EGFR,  
VEGFR2, HER2, and EphB4
NCT01487174 III XL647 or erlotinib in subjects with Stage IIIB/IV NSCLC, 
progressed after first- or second-line chemotherapy
Abbreviations: ADC, adenocarcinoma; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EphB4, ephrin type-B receptor-4; HDAC, histone 
deacetylase; HER, human epidermal growth factor receptor; NSCLC, non-small cell lung cancer; pts, patients; RT, radiotherapy; TKI, tyrosine kinase inhibitor; VEGFR, 
vascular endothelial growth factor receptor.
to pemetrexed/platinum as first-line therapy. Furthermore, 
a randomized, open label, Phase III study is being performed 
to compare first-line cisplatin and pemetrexed for six cycles 
followed by gefitinib for six courses (21 days each) versus 
gefitinib alone for six courses (21 days each) in East Asian; 
never or light ex-smoker patients with locally advanced or 
metastatic nonsquamous NSCLC (NCT01017874). Results 
are expected in 2013.
In recent years, several trials have evaluated gefitinib in 
the second-line setting of NSCLC. In the INTEREST (Iressa® 
NSCLC Trial Evaluating Response and Survival against 
Taxotere®)24 and V-15-3225 studies, gefitinib showed an 
efficacy similar to docetaxel when used in patients previously 
treated with platinum-based chemotherapy. In the ISTANA 
(Iressa® as Second-line Therapy in Advanced NSCLC – 
Korea) study, second-line gefitinib significantly prolonged 
PFS when compared with docetaxel in Korean patients.26 In 
the Phase II SIGN (Second-line Indication of Gefitinib in 
NSCLC) trial,27 141 patients who had previously received 
one chemotherapy regimen were randomly assigned to 
receive gefitinib (250 mg/day) or docetaxel (75 mg/m2 every 
3 weeks). In the gefitinib and docetaxel groups, respectively, 
the ORR was 13.2% and 13.7%, median overall survival 
(OS) was 7.5 months and 7.1 months, and quality-of-life 
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Figure 1 The distribution of ongoing clinical studies in non-small cell lung cancer patients (http://www.clinicaltrials.gov).
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Figure 2 The distribution of ongoing studies of (A) erlotinib and (B) gefitinib (http://www.clinicaltrials.gov).
improvement rates was 33.8% and 26.0%. The incidence 
of drug-related AEs was lower in patients treated with gefi-
tinib (all grades: 51.5% versus 78.9%; Grade III/IV: 8.8% 
versus 25.4%). Furthermore, in the ISEL (Iressa® Survival 
Evaluation in Lung Cancer) trial, gefitinib demonstrated no 
improvement in OS or other outcomes compared with placebo 
when used as second- or third-line therapy. However, in this 
study the enrolment was restricted to patients refractory or 
intolerant to their first or second line of therapy and not suit-
able for further chemotherapy, as these patients are commonly 
associated with a very poor prognosis.28
Currently, a Phase II trial (NCT00891579) is recruiting 
patients in order to compare pemetrexed versus gefitinib in 
patients with locally advanced or metastatic NSCLC previ-
ously treated with platinum-based chemotherapy and without 
EGFR mutations.
In regard to the use of gefitinib in association with first-line 
chemotherapy, the results of the INTACT (Iressa® NSCLC 
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Trial Assessing Combination Treatment) 129 and 2 studies30 
showed that gefitinib did not significantly improve OS or 
time to progression when added to first-line paclitaxel plus 
carboplatin or gemcitabine plus cisplatin, respectively. 
 Furthermore, Simon et al evaluated the combination of gefi-
tinib and docetaxel in elderly NSCLC patients, obtaining a 
median PFS of 6.9 months and a median OS of 9.6 months.31 
At present, another Phase II trial (NCT01469000) is investi-
gating gefitinib versus gefitinib plus pemetrexed in the first-
line setting of EGFR mutation-positive NSCLC.
Gefitinib is also under evaluation in squamous NSCLC 
patients who failed first-line chemotherapy (NCT01485809), 
in association with radiotherapy in EGFR mutation-positive 
locally advanced NSCLC (NCT01391260), as adjuvant ther-
apy in comparison with vinorelbine/platinum in Stage II–IIIA 
(N1–N2) NSCLC with EGFR mutation (NCT01405079), 
and as a rechallenge in patients who responded to first-line 
gefitinib (NCT01530334).
Clinical results and ongoing studies 
with erlotinib in NSCLC
Erlotinib is a low molecular weight, orally bioavailable 
inhibitor of EGFR and it was the first targeted agent approved 
for second- and third-line treatment of NSCLC in patients 
unselected for EGFR mutations. Based on the results of the 
BR.21 trial,32 erlotinib was approved by the US Food and 
Drug Administration in 2004 for the treatment of patients 
with locally advanced or metastatic NSCLC after failure of 
at least one prior chemotherapy regimen, without restrictions 
in terms of molecular profile.
In 2009, Rosell et al obtained a median OS of 28.0 months 
in patients receiving erlotinib as first-line therapy, as com-
pared to 27.0 months for those treated with erlotinib after 
failure of prior chemotherapy.33 Results from the Optimal 
study, which compared erlotinib with carboplatin plus gem-
citabine in Chinese patients with NSCLC and EGFR muta-
tions, showed a median PFS of 13.1 months for erlotinib and 
4.6 months for standard chemotherapy. Erlotinib was superior 
also in terms of ORR (83% versus 36%) and tolerability.16 
On the other hand, the EURTAC (European Erlotinib Versus 
Chemotherapy) study compared erlotinib with platinum-
based chemotherapy as a first-line treatment of non-Asian 
patients with advanced EGFR-mutant NSCLC. Median 
PFS was 9.7 months in the erlotinib group and 5.2 months 
in the standard chemotherapy group. The main severe AEs 
were rash (13% with erlotinib and 0% with chemotherapy), 
neutropenia (0% versus 22%), and anemia (1% versus 4%).17 
However, erlotinib did not improve OS when added to best 
supportive care, as compared with best supportive care alone, 
in chemotherapy-naive patients with poor performance status 
or who were unfit for platinum-based chemotherapy.34
Concerning the use of erlotinib in association with first-
line chemotherapy, the drug did not confer a significant overall 
benefit when it was added to first-line  carboplatin–paclitaxel 
in the TRIBUTE (Tarceva® Responses in Conjunction With 
Paclitaxel and Carboplatin) study35 or cisplatin–gemcitabine 
in the TALENT (Tarceva® Lung Cancer Investigation) study.36 
Nevertheless, the analysis of a subpopulation in both stud-
ies showed significant OS benefits in never smokers treated 
with erlotinib.
Two additional studies, SATURN (Sequential Tarceva® 
in Unresectable NSCLC)37 and ATLAS (A Study Compar-
ing Bevacizumab Therapy With or Without Erlotinib for 
First-line Treatment of NSCLC),38 investigated the efficacy 
of erlotinib as maintenance therapy in locally advanced or 
metastatic NSCLC patients with stable disease (SD) fol-
lowing standard platinum-based first-line chemotherapy. 
Both trials reported increased PFS in patients treated with 
erlotinib, with the highest PFS in EGFR-mutated cases. 
On the other hand, the Phase III study of gemcitabine or 
erlotinib as maintenance therapy versus observation after 
cisplatin–gemcitabine induction chemotherapy led by Perol 
et al showed a nonsignificant OS benefit.39
In the TORCH (Tarceva® or Chemotherapy for the Treat-
ment of Advanced NSCLC) study, conducted in unselected 
patients with advanced NSCLC, first-line erlotinib followed 
by second-line cisplatin–gemcitabine was inferior to first-
line cisplatin–gemcitabine followed by second-line erlotinib. 
 Interestingly, a relevant proportion of patients assigned to first-
line chemotherapy did not receive second-line treatment.40 In 
the same year, the Phase III TITAN (Tarceva® in Treatment 
of Advanced NSCLC) study, comparing erlotinib versus doc-
etaxel or pemetrexed in chemorefractory NSCLC, showed no 
differences in PFS in both arms.41 Wu et al recently published 
the results of a Phase II trial of erlotinib as second-line treat-
ment in patients with advanced NSCLC and asymptomatic 
brain metastases, showing a PFS of 15.2 months in EGFR 
mutation-positive patients versus 4.4 months in EGFR wild 
type disease patients and a median OS of 18.9 months. The 
most common AEs were rash (77.1%), paronychia (20.8%), 
hyperbilirubinemia (16.7%), and diarrhea (14.6%).42
Novel small molecule EGFR 
inhibitors for NSCLC
Patients with EGFR-mutant lung cancer develop disease 
progression after a median of 10–14 months on TKIs, due 
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to the development of acquired resistance to EGFR TKIs.6,33 
Several possible mechanisms underlying such resistance have 
been identified, the most common being the development of 
an EGFR T790M gatekeeper mutation in over 50% of cases. 
T790M mutation occurs by substitution of the amino acid 
threonine by methionine in amino acid position 790 (T790M) 
on exon 2043 and is similar to the KIT T670I gatekeeper muta-
tion observed in imatinib-resistant gastrointestinal stromal 
tumor.44 Although the majority of EGFR mutations reduce 
the receptor’s affinity to ATP, the acquisition of T790M 
restores EGFR affinity for ATP to wild type levels, reducing 
the effect of TKIs.45 Interestingly, despite the presence of 
the T790M mutation possibly increasing the oncogenicity 
of TKI-sensitive mutations by a synergistic kinase activity, 
T790M-harboring tumors can display an indolent nature.46 
Another well-described mechanism of acquired resistance 
is represented by c-Met amplification, which can bypass the 
inhibition of EGFR by coupling to human epidermal growth 
factor receptor-3 (HER3), thus leading to sustained activa-
tion of the phosphatidylinositol 3-kinase (PI3K)/Akt (also 
known as protein kinase B) signaling pathway.19 Although 
the amplification of c-Met is rare in baseline tumor samples 
from EGFR TKI-naive patients, it is observed in up to 20% 
of tumor samples after treatment with EGFR TKIs.47 Several 
other mechanisms of acquired resistance, including muta-
tions of PIK3CA, loss of phosphatase and tensin homolog 
expression, and altered insulin-like growth factor (IGF) 
receptor signaling have been identified in NSCLC patients 
treated with TKIs.18
Recently, a number of clinical trials have been initiated 
to explore various strategies to overcome secondary resis-
tance, including vertical and pan-HER inhibition and the use 
of irreversible EGFR inhibitors, such as afatinib, which is 
able to bind to EGFR, HER2, and HER4 and, in contrast to 
gefitinib and erlotinib, also to bind to receptors carrying the 
T790M mutation. The characteristics of these novel promis-
ing agents are described in sections below.
Afatinib and other EGFR/HER2 inhibitors
The interdependent signaling that occurs between EGFR and 
HER2 provides a rationale for the simultaneous inhibition 
of these receptors with reversible and irreversible inhibitors. 
Thus, HER2 is the preferred partner for all of the HER family 
members, including EGFR, and is able to regulate and diver-
sify EGFR downstream signaling; in addition, EGFR mitotic 
signals can be augmented by the coexpression of HER2.48
Afatinib (BIBW2992) is an irreversible dual EGFR/
HER2 inhibitor. In the LUX-Lung 2 Phase II trial, afatinib 
showed activity in the treatment of patients with advanced 
lung ADC with EGFR mutations, especially in patients with 
deletion 19 or L858R mutation.48 Recently, a Phase II trial 
(NCT00796549) in advanced EGFR-mutant NSCLC has 
been completed, but results are still to come. Another Phase I 
study (NCT01647711) is ongoing in advanced NSCLC with 
T790M-mutant patients treated with intermittent high dose 
of afatinib.
In the Ascent trial (NCT01553942), afatinib is adminis-
tered before concurrent chemoradiation and after surgery in 
Stage III EGFR-mutant NSCLC. Additionally, another ongo-
ing Phase II trial (NCT00730925) is exploring the efficacy 
of afatinib in patients with advanced NSCLC whose tumors 
harbor activating EGFR or HER2/neu receptor mutations 
and in patients with EGFR fluorescent in situ hybridization-
positive tumors with no EGFR mutations.
Finally, afatinib is also under evaluation in expanded 
access (NCT01649284), in a study of afatinib-induced 
mechanisms of resistance (NCT01074177), as neoadjuvant 
therapy (NCT01480141), and as third-line treatment of 
patients with Stage IIIB/IV ADC of the lung harboring wild 
type EGFR (NCT01003899).
Besides afatinib, several other EGFR/HER2 kinase inhibi-
tors are currently under development, most of them in early 
clinical phases. Among them, neratinib, an oral irreversible 
dual EGFR/HER2 inhibitor, demonstrated low activity in 
NSCLC patients with prior benefit from TKIs and in TKI-naive 
patients. On the other hand, CUDC-101 – a potent multitarget 
inhibitor of EGFR, HER2, and histone deacetylase (HDAC) – 
is currently being studied in a Phase I trial (NCT01171924) in 
advanced solid tumors including NSCLC.
Icotinib
The use of icotinib (BPI-2009H), a potent and specific EGFR 
TKI, has been demonstrated to provide similar efficacy to 
gefitinib, but with better tolerability, in NSCLC patients 
previously treated with one or two chemotherapy agents.49 
At present, icotinib is being investigated in a Phase IV trial 
(NCT01665417) as first-line and maintenance therapy in 
EGFR-mutated patients with lung ADC. Another Phase IV 
trial (NCT01465243) is evaluating the efficacy and safety of 
dose escalation of icotinib in advanced NSCLC patients who 
failed with icotinib at routine dose. Furthermore, icotinib is 
being studied in several trials alone (NCT01688713), in com-
parison (NCT01724801), or in combination (NCT01516983 
and NCT01514877) with whole brain radiation in EGFR 
mutation-positive patients with brain metastasis and in first-
line therapy of elderly NSCLC patients (NCT01646450).
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Mutant-selective EGFR inhibitors
The group of emerging mutant-selective EGFR inhibitors 
include HM61713 and CO-1686. HM61713 is a mutant-
selective EGFR inhibitor, currently being studied in patients 
progressed after at least two prior chemotherapy and/or 
EGFR TKI regimens (NCT01588145). Otherwise, CO-1686 
is a novel irreversible mutant-selective inhibitor of EGFR, 
able to target both the initial activating EGFR mutations as 
well as the T790M secondary acquired resistance mutation. 
To investigate its use as a single agent, CO-1686 is being 
evaluated in a Phase I/II trial in EGFR-mutant NSCLC 
patients previously treated with first-line gefitinib or erlotinib 
(NCT01526928).
Pan-HER inhibitors and multitargeted TKIs
Several pan-HER inhibitors and multitargeted agents are 
in clinical development. In regard to dacomitinib (PF-
00299804), an irreversible pan-HER inhibitor, as a single 
agent, Ramalingam et al recently published the results from 
a Phase II study comparing dacomitinib versus erlotinib in 
patients with NSCLC.54 In this study, dacomitinib signifi-
cantly improved PFS as compared to erlotinib (2.86 months 
versus 1.91 months), with a low rate of serious AEs in both 
treatment arms. At present, dacomitinib is being studied in a 
Phase III trial (NCT01000025) in Stage IIIB/IV NSCLC after 
failure of up to a maximum of three lines of chemotherapy 
and at least one with erlotinib or gefitinib. Another ongoing 
Phase II trial (NCT00818441) is assessing the efficacy of 
dacomitinib in ADC selected patients (nonsmokers, former 
light smokers, EGFR-activating mutation-positive patients, 
or patients with HER2 amplification or mutation). The group 
of novel pan-HER inhibitors also includes NOV120101 
(poziotinib). Recently, a Phase II study has been activated in 
order to assess its efficacy in NSCLC patients with acquired 
resistance to first-generation EGFR TKIs (NCT01718847).
The list of multitargeted agents being evaluated in 
NSCLC patients includes vandetanib, AP26113, XL647, 
and BMS-690514. Vandetanib, also known as ZD6474, is 
an antagonist of EGFR, vascular endothelial growth fac-
tor receptor (VEGFR), and rearranged during transfection 
tyrosine kinases. In 2008, Heymach et al tested vandetanib 
alone or in combination with paclitaxel and carboplatin as 
first-line treatment for advanced NSCLC, without observ-
ing significant differences in terms of efficacy.50 In 2010, 
Herbst et al performed a randomized Phase III trial to evaluate 
docetaxel versus docetaxel plus vandetanib as second-line 
treatment in 1391 patients with advanced NSCLC. The 
addition of vandetanib to docetaxel resulted in an increased 
PFS (4 months versus 3.2 months). Grade III/IV rash (9% 
versus 1%), neutropenia (29% versus 24%), leukopenia 
(14% versus 11%), and febrile neutropenia (9% versus 7%) 
were more common in patients treated with vandetanib plus 
docetaxel.51 Additionally, two Phase III trials that evalu-
ated vandetanib versus placebo in patients with advanced 
NSCLC after prior therapy with an EGFR TKI52 and versus 
erlotinib after treatment failure with up to two chemotherapy 
regimens53 did not demonstrate OS or PFS benefits. At 
present, vandetanib is under evaluation in comparison with 
erlotinib in NSCLC patients who failed at least one prior 
chemotherapy (NCT00364351) and in combination with 
pemetrexed versus pemetrexed alone in the second-line treat-
ment of NSCLC patients (NCT00418886).
In the Phase II trial led by Pietanza et al, XL647 – an oral 
small-molecule inhibitor of multiple TKI, including EGFR, 
VEGFR2, HER2, and ephrin type-B receptor-4 – showed a 
PFS of 5.2 months and an ORR of 20% in treatment-naive 
NSCLC patients.55 By contrast, XL647 showed minimal 
effects in patients who developed acquired resistance to 
erlotinib or gefitinib.56 At present, a randomized Phase III 
trial (NCT01487174) is recruiting patients to compare XL647 
and erlotinib in subjects with Stage IIIB/IV NSCLC with 
progression after first- or second-line chemotherapy.
On the other hand, AP26113 is a dual anaplastic lym-
phoma kinase/EGFR inhibitor, currently being evaluated 
in a Phase I/II study of NSCLC and other malignancies 
(NCT01449461). BMS-690514 is an EGFR and VEGFR TKI, 
currently being compared with erlotinib (NCT00743938) in 
previously treated NSCLC patients and in EGFR mutation-
positive patients treated with prior gefitinib or erlotinib 
(NCT01167244).
Combination therapy with gefitinib 
and TKIs or other agents
Several trials have been performed to assess the efficacy 
of gefitinib in combined approaches. In 2007, Adjei et al 
explored the combination of gefitinib and sorafenib in a 
Phase I study enrolling 31 patients with refractory or recur-
rent NSCLC. Among the enrolled patients, one had partial 
response (PR) and 20 had SD, with a low rate of serious 
AEs.56
To assess the combined effects of gefitinib and mam-
malian target of rapamycin (mTOR) inhibitors, Price et al 
published the results of a Phase II study on 62 patients treated 
with everolimus 5 mg and gefitinib 250 mg. They observed 
13% PR, with a median PFS of 4 months.57 At present, 
gefitinib is being studied in combination with BKM-120 
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(NCT01570296), an oral pan-class I PI3K inhibitor, and with 
MK2206 (NCT01147211), an Akt inhibitor, in patients with 
advanced NSCLC.
In 2011, a randomized Phase II study of gefitinib plus sim-
vastatin versus gefitinib alone in previously treated patients 
with advanced NSCLC showed higher RR and longer PFS 
in the group of patients treated with simvastatin, although 
the difference was not statistically significant.58
Based on the evidence that prostaglandin E
2
 regulates 
cell migration via the intracellular activation of the EGFR,59 
Agarwala et al performed a Phase II trial of gefitinib 
plus celecoxib, a selective cyclooxygenase-2 inhibitor in 
 chemotherapy-naive patients with Stage IIIB/IV NSCLC. 
In this study, the overall efficacy was lower than historical 
controls of combination chemotherapy (RR was 16%, median 
PFS was 3.2 months, and OS was 7.0 months).60
In December 2012, 13 studies were being performed to 
assess the combined effects of gefitinib with other targeted 
agents, such as anti-EGFR monoclonal antibody (mAb) nimo-
tuzumab (NCT01498562), poly(adenosine diphosphate ribose) 
polymerase inhibitor olaparib (AZD2281) (NCT01513174), 
c-Met inhibitor INC280 (NCT01610336), anti-hepatocyte 
growth factor mAb ficlatuzumab (AV299) (NCT01039948), 
HDAC inhibitor vorinostat (NCT01027676), and autophagic 
inhibitor hydroxychloroquine (NCT00809237).
Combinations of erlotinib  
with other TKIs
At this time, several TKIs are being studied in combination 
with erlotinib in NSCLC (Table 2). In this scenario, the 
efficacy and safety of sorafenib plus erlotinib was tested 
in a double-blind Phase II trial, observing little difference 
in terms of ORR and PFS as compared to erlotinib alone.61 
 Additionally, sorafenib was evaluated in combination with 
erlotinib or gemcitabine in elderly unselected untreated 
patients with advanced NSCLC, demonstrating to be feasible 
and effective in this compound.62
Again, sunitinib in combination with erlotinib was 
compared to erlotinib/placebo in a Phase III trial led by 
Scagliotti et al. In this study, 960 patients were randomized 
to receive sunitinib 37.5 mg/day plus erlotinib 150 mg/day or 
placebo plus erlotinib 150 mg/day. In patients treated with 
Table 2 Combinations of erlotinib and other tyrosine kinase inhibitors under evaluation for non-small cell lung cancer (http://www.
clinicaltrials.gov)
Agent Description Trial Phase Design
Pazopanib Multiple TKIs, including VEGFRs,  
PDGFR, and c-kit
NCT01027598 II Erlotinib/pazopanib versus erlotinib/placebo in pretreated 
NSCLC pts
NCT00619424 Ib Pazopanib in combination with either erlotinib or pemetrexed 
in NSCLC pts
Dovitinib Multiple TKIs, including FGFR  
and VEGFR TKI
NCT01515969 I Pts with advanced NSCLC who have failed any number of 
prior therapies
Tivozanib VEGFR1, VEGFR2, VEGFR3, c-kit,  
and PDGFR-β TKIs
NCT01728181 I/II Untreated pts with advanced NSCLC
Tivantinib c-Met inhibitor NCT01580735 II EGFR mutation-positive NSCLC
NCT01244191 III Tivantinib and erlotinib versus erlotinib in EGFR mutation-
positive NSCLC
NCT01395758 II Erlotinib plus ARQ 197 versus single-agent chemotherapy 
(pemetrexed, docetaxel, or gemcitabine) in previously treated 
KRAS mutation-positive subjects with locally advanced or 
metastatic NSCLC
Cabozantinib Dual c-Met/VEGFR2 inhibitor NCT00596648 I/II Cabozantinib with or without erlotinib in adults with NSCLC
NCT01708954 II Erlotinib hydrochloride and cabozantinib alone or in combination 
as second- or third-line therapy in pts with Stage IV NSCLC
Foretinib Dual c-Met/VEGFR2 inhibitor NCT01068587 I/II Erlotinib with or without foretinib in pts with advanced 
NSCLC that has not responded to previous chemotherapy
MGCD265 wild type and mutant c-Met, VEGFR1,  
VEGFR2, VEGFR3, Ron, and Tie-2 TKIs
NCT00975767 I/II MGCD265 and erlotinib or docetaxel in subjects with 
advanced solid tumors or NSCLC
OSI-906 Dual TKI of IGF-1R and IR NCT01186861 II Erlotinib with or without OSI-906 in pts with nonprogression 
following four cycles of platinum-based chemotherapy
OSI-930 Inhibitor of c-kit and KDR NCT00603356 I Pts with advanced NSCLC who have failed any number of 
prior therapies
Abbreviations: FGFR, fibroblast growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; IR, insulin receptor; KDR, kinase insert domain receptor; c-Met, 
mesenchymal–epithelial transition factor; NSCLC, non-small cell lung cancer; pts, patients; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor; 
VEGFR, vascular endothelial growth factor receptor.
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sunitinib plus erlotinib, median OS was 9.0 months, median 
PFS was 3.6 months, and ORR was 10.6%. In the other 
group, OS was 8.5 months, median PFS was 2.0 months, 
and ORR was 6.9%. Severe treatment-related AEs, such as 
rash/dermatitis, diarrhea, and asthenia/fatigue, were more 
frequent in the sunitinib/erlotinib arm.63
The efficacy of pazopanib, a potent and selective multi-
targeted TKI of VEGFR1, VEGFR2, VEGFR3, platelet-
derived growth factor receptor-α/β, and c-kit, in NSCLC 
patients has been evaluated in several trials. As monotherapy, 
pazopanib was demonstrated to be active in treatment-naive 
patients with Stage I/II resectable NSCLC.64 In 2012, the 
combination of pazopanib and erlotinib was evaluated in 
a Phase Ib study, demonstrating a manageable toxicity 
profile.64 Currently, another Phase II trial (NCT01027598) 
is ongoing to test erlotinib/pazopanib or erlotinib/placebo 
in pretreated NSCLC patients. The results of a Phase Ib 
trial (NCT00619424) evaluating pazopanib in combination 
with either erlotinib or pemetrexed in NSCLC patients are 
still to come. At this time, pazopanib is being studied in 
combination with vinorelbine (NCT01060514) or paclitaxel 
(NCT00866528 and NCT01179269), in NSCLC third-line 
setting (NCT01049776), in comparison with pemetrexed 
as maintenance therapy in Stage IV nonsquamous NSCLC 
(NCT01313663), as second-line therapy after first-line 
chemotherapy (NCT01208064) or treatments containing 
bevacizumab (NCT01262820), and as adjuvant therapy 
(NCT00775307).
Currently, two studies are investigating the combined 
effects of erlotinib and dovitinib, a fibroblast growth factor 
receptor and VEGFR inhibitor, and tivozanib (AV-951), 
an orally bioavailable potent inhibitor of VEGFR1, 
VEGFR2, VEGFR3, c-kit, and platelet-derived growth fac-
tor receptor-β, in advanced NSCLC (NCT01515969 and 
NCT01728181, respectively).
In regard to the possibility of combining erlotinib and 
c-Met TKIs, the combination of erlotinib and tivantinib 
(ARQ 197) demonstrated to be active, especially among 
patients with KRAS mutations, although no significant PFS 
differences were found in erlotinib alone.65 At present, this 
combination is being evaluated in EGFR mutation-positive 
NSCLC (NCT01580735 and NCT01244191) and in previ-
ously treated KRAS mutation-positive subjects with locally 
advanced or metastatic NSCLC (NCT01395758).
Moreover, erlotinib is also being evaluated in combina-
tion with cabozantinib (XL184), foretinib (XL880), and 
MGCD265. Cabozantinib is a potent inhibitor of c-Met 
and VEGFR2, under evaluation in patients with progressive 
 disease following prior Response Evaluation Criteria in Solid 
Tumors (RECIST) response to monotherapy with erlotinib 
(NCT00596648) and as second/third-line therapy for EGFR 
mutation-negative patients who received up to two lines of 
prior chemotherapy (NCT01708954). Foretinib, a dual c-Met/
VEGFR2 inhibitor, is currently being studied in patients with 
advanced NSCLC that has not responded to previous che-
motherapy (NCT01068587). Otherwise, MGCD265 targets 
wild type and mutant c-Met, VEGFR1, VEGFR2, VEGFR3, 
Ron, and Tie-2 and is currently being evaluated with erlotinib 
in patients with advanced malignancies including NCSLC 
(NCT00975767).
Among novel TKIs, erlotinib is currently being studied 
in combination with OSI-906, a dual TKI of IGF-1 receptor 
and insulin receptor as maintenance therapy in patients with 
nonprogression following four cycles of platinum-based 
chemotherapy (NCT01186861) and OSI-930, an inhibitor of 
c-kit and kinase insert domain receptor (NCT00603356).
Interestingly, preliminary results of combined therapy 
with erlotinib and crizotinib, an anaplastic lymphoma kinase 
and C-ros oncogene 1 (ROS1) TKI, showed signs of activity in 
pretreated NSCLC patients. Among the 25 enrolled patients, 
Ou et al observed one patient with PR and eight with SD. 
The most common AEs (all grades) were diarrhea (72%), 
rash (56%), and fatigue (44%).67
Combination of erlotinib and mAbs
The combination of erlotinib and bevacizumab has been 
tested as first-line therapy in advanced nonsquamous NSCLC 
Stage IIIB/IV. In a recent study by Zappa et al, among the 
101 enrolled patients, 73 had SD, one had complete remis-
sion, and 17 had PR, with acceptable toxicity.68 The use of 
bevacizumab and erlotinib in the second-line setting has been 
explored in a randomized Phase III study led by Herbst et al,69 
comparing this combination versus erlotinib alone after failure 
of standard first-line chemotherapy. They did not observe an 
OS benefit with the addition of bevacizumab, with 42% in 
the bevacizumab group reporting serious AEs as compared 
to 36% in the control group. Recently, a Phase II study of 
erlotinib and bevacizumab in newly diagnosed performance 
status two or elderly patients with nonsquamous NSCLC 
has been performed, registering insufficient activity in the 
absence of known EGFR-activating mutations.70 At pres-
ent, an ongoing Phase II trial is testing this combination in 
EGFR-mutant NSCLC patients (NCT01562028). Recently, 
the addition of toll-like receptor-9 agonist IMO-2055 to 
erlotinib/bevacizumab has been demonstrated to be effective 
(RR was 12% with 79% disease control) and well tolerated, 
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registering 9% fatigue, 9% diarrhea, and 6% anemia and 
dyspnea as the most frequent Grade III/IV AEs.71
Furthermore, erlotinib has been tested in combination 
with anti-IGF-1 receptor mAbs IMC-A12 (cixutumumab) 
and R1507, without demonstrating to be active in advanced 
NSCLC.72,73 The studies evaluating the combination of 
erlotinib and anti-IGF-1 receptor mAb f igitumumab 
(NCT00673049) and dalotuzumab (NCT00654420) have 
just terminated and results are expected in 2013.
Erlotinib has also being tested in combination 
with several agents including anti-c-Met mAb onar-
tuzumab, anti-HER3 mAbs MM-121(NCT00994123) 
and U3-1287 (NCT01211483), anti-EGFR mAb cetux-
imab (NCT00408499), anti-HER2 mAb pertuzumab 
(NCT00855894), and anti-programmed death-1 mAb BMS-
936558 (MDX-1106) (NCT01454102).
Combination of erlotinib  
and mTOR, PI3K, and Akt inhibitors
Among the 74 NSCLC patients treated with the combination 
of everolimus and erlotinib as second- or third-line therapy in 
a Phase I trial led by Papadimitrakopoulou et al, nine patients 
achieved complete remission/PR and 28 had SD, with accept-
able tolerability.74 LY2584702, an orally available inhibitor 
of p70S6K signaling, is currently being studied in combina-
tion with erlotinib or everolimus in patients with advanced 
solid tumors including NSCLC (NCT01115803).
Furthermore, erlotinib is currently being studied in 
NSCLC patients in combination with PI3K inhibitors BKM-
120 (NCT01487265), XL-147 (NCT00692640), MK2206 
(NCT01294306), GDC-0941 (NCT00975182), and dual 
PI3K/mTOR inhibitor XL765 (NCT00777699). Among 
novel agents, CC-223, a novel dual mTOR complex-1 
and -2 inhibitor, is currently being studied in combina-
tion with erlotinib or oral azacitidine in advanced NSCLC 
(NCT01545947).
Combination of erlotinib  
with other agents
The combination of erlotinib and dasatinib, an Src and 
multikinase inhibitor, has been tested in a Phase I/II trial, 
obtaining a disease control rate of 63%, with a tolerable 
toxicity profile. As a single agent, dasatinib is the subject 
of two Phase II trials in advanced squamous cell carcinoma 
NSCLC (NCT01491633) and pretreated NSCLC patients 
(NCT00787267).
Additionally, the combination of erlotinib and selu-
metinib (AZD6244), a small molecule mitogen-activated 
 protein kinase kinase-1 and -2 inhibitor, is being evaluated in 
advanced NSCLC, including KRAS mutated lung cancer that 
has not responded to standard therapy (NCT01229150).
Erlotinib has been also tested in combination with 
enzastaurin, a selective protein kinase Cβ inhibitor, and 
bortezomib, a proteasome inhibitor, without improving 
PFS and OS when compared to erlotinib alone,75–77 as well 
as entinostat, an HDAC inhibitor.78 Two Phase I/II trials of 
HDAC inhibitor vorinostat (NCT00503971) and belinostat 
(NCT01188707) in combination with erlotinib have been 
terminated but results are still to come.
The list of novel agents under study in combination with 
erlotinib also includes:
–	 Tosedostat (CHR-2797), a novel metalloenzyme inhibitor 
(NCT00522938)
–	 RO4929097, a selective inhibitor of γ-secretase inhibiting 
Notch signaling (NCT01193881)
–	 MLN8237 (alisertib), a selective Aurora A inhibitor 
(NCT01471964)
–	 Fulvestrant ,  an estrogen receptor antagonist 
(NCT00100854)
–	 AT-101, an orally bioavailable pan-Bcl-2 inhibitor 
(NCT00988169)
–	 AUY922, a highly potent heat shock protein-90 inhibitor 
(NCT01259089)
–	 CS-7017, a selective peroxisome proliferator-activated 
receptor-γ (NCT01101334 and NCT01199068)
–	 Selective cyclooxygenase-2 inhibitors celecoxib 
(NCT00499655) and apricoxib (NCT00652340)
–	 A u t o p h a g i c  i n h i b i t o r  hy d r ox y c h l o r o q u i n e 
(NCT00977470).
Combinations of novel small 
molecule EGFR inhibitors
Among the 64 studies on novel small molecule EGFR 
inhibitors for NSCLC, nine trials have been performed to 
assess the use of these emerging agents in combination 
with targeted therapies. In this setting, afatinib, an irrevers-
ible dual EGFR/HER2 inhibitor, is the subject of a Phase I 
trial testing its combination with mTOR inhibitor sirolimus 
(NCT00993499). Preliminary results on its combination with 
cetuximab showed afatinib/cetuximab is tolerable and effec-
tive in NSCLC patients with acquired resistance to erlotinib 
or gefitinib.79 In addition, afatinib, used alone or in combina-
tion with simvastatin, is currently being studied in previously 
treated non-ADC NSCLC patients (NCT01156545).
Vandetanib, a TKI of rearranged during transfection, 
VEGFR, and EGFR signaling, is currently being studied 
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in combination with mitogen-activated protein kinase 
kinase inhibitor selumetinib (AZD6244) in a Phase I study 
(NCT01586624) of patients with solid tumors including 
NSCLC. Furthermore, the irreversible human pan-HER 
inhibitor dacomitinib (PF-00299804) is being evaluated in 
combination with PF-02341066, a selective small molecule 
oral inhibitor of the c-Met/hepatocyte growth factor receptor 
and anaplastic lymphoma kinase receptor tyrosine kinases 
(NCT01441128 and NCT01121575), and figitumumab 
(CP-751, 871), a mAb directed against IGF-1 receptor 
(NCT00728390).
Discussion
Over recent years, basic scientific research has dramatically 
increased the knowledge of the pathogenesis of lung cancer 
and enhanced the understanding of the cellular pathways 
involved in this process. The development of small molecule 
EGFR inhibitors has opened novel therapeutic scenarios, 
thus improving patient outcomes. The histological and 
molecular heterogeneity of NSCLC tumors is an open prob-
lem, as shown by the large number of ongoing trials on the 
molecular status of patients treated with EGFR TKIs across 
all lines. However, despite dramatic and sustained responses 
and the discovery of specific patient subgroups that may 
derive clinical benefit, resistance to first-generation EGFR 
TKIs inevitably develops. Advances in the knowledge of 
acquired mechanisms of resistance to these agents have led 
to the development of second-generation molecular-targeted 
agents aimed to overcome such resistance. These novel 
agents include irreversible EGFR inhibitors able to block 
receptor kinase activity through binding of the ATP site 
and inducing covalent modification of nucleophilic cysteine 
residues in the catalytic domains of EGFR family members. 
This bond seems to allow local persistence of high drug 
concentrations, thus permitting the inhibition of the cata-
lytic function even in the presence of the T790M mutation.
It remains to be demonstrated whether this newer generation 
of agents will play a role as a superior inhibitor of EGFR by 
overcoming resistance or whether they will register wider 
effectiveness by blocking both EGFR and HER2 signaling. 
Preclinical evidence supports the concept that the concurrent 
inhibition of multiple HER family members may be more 
effective than sole EGFR inhibition. Moreover, blocking 
both the intracellular and the extracellular EGFR domains 
by a “vertical blockade” might open an additional strategy 
to possibly overcoming resistance. Randomized trials of 
irreversible inhibitors or mutant-selective or multitargeted 
agents versus erlotinib or gefitinib in prospectively identified 
mutant EGFR are required to explore their potential for the 
treatment of NSCLC.
Presently, EGFR TKIs are the subject of about a quarter 
of all active clinical trials in NSCLC. About half of those 
concern the use of these agents as monotherapy and a quar-
ter are investigating their use in combined approaches. The 
small number of trials on sequential therapy may be partially 
explained by the longer duration and the larger accrual needed 
by clinical studies on sequences.
Additionally, two other points need to be underlined. 
First, the high number of studies on already approved 
targeted agents gefitinib and erlotinib: these trials focus 
on the potential use of these therapies at different doses or 
schedules from current standards or in specific subpopula-
tions of NSCLC patients. In this regard, the development of 
biomarkers of tumor response may represent a crucial step 
forward in the management of NSCLC, thus optimizing 
treatment outcomes with approved agents and improving 
their efficacy in combined or sequential strategies. Second, 
it is important to mention the small number of trials on the 
prophylaxis and treatment of TKI-related AEs. The use of 
these agents requires early and appropriate management 
of side effects in order to improve patients’ quality of life 
and to avoid unnecessary dose reductions and transitory or 
definitive treatment discontinuations.
The small number of studies on the use of EGFR TKIs as 
neoadjuvant and adjuvant therapies is partially explained by 
the complexity of standardizing multidisciplinary approaches 
and by the necessary long observational period, especially 
in the adjuvant setting. Nevertheless, results from these 
ongoing studies are dramatically needed, even considering 
the stunted number of complete responses demonstrated 
by current and first incoming agents. Thus, if adjuvant and 
neoadjuvant trials will demonstrate an advantage in terms 
of optimizing surgical approaches and increasing time to 
relapse after surgery, they would definitively have a major 
impact on present therapeutic approaches.
Conclusion
Data gathered from ongoing trials will surely improve the 
management of NSCLC patients, even if it is difficult to 
define the relevance of each one’s individual contribution. 
Preliminary results from ongoing trials thus constitute a basis 
for moderate enthusiasm, but a dramatic improvement of 
NSCLC patient outcomes seems still so far away.
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